CBO, Mission Therapeutics Ltd
Paul has over 25 years’ leadership experience in business development. Currently he is CBO for Mission Therapeutics, a VC/corporate venture backed UK pharmaceutical company. Previously he was EVP for a publicly-listed European pharmaceutical company during its transition from an early-stage biotech to a profitable company with commercial sales.
He has a track record of leveraging platform technologies and R&D assets to grow and sustain companies. He has led the execution of multiple partnerships: to a total value of $4.5B, the majority with major pharma and consistently at the leading edge of deal trends. Two partnerships have resulted in drugs reaching the market, including the blockbuster Olysio®. He has been a member of executive teams that have raised over $200M.
Paul had an initial research career and is the inventor of two antibody therapeutics in late stage development for cancer indications. He carried out his PhD and postdoc in biochemistry at the University of Cambridge.
(+44) 1223 496 000
Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom
01223 813 557